Nicolet Bankshares Inc. Has $1.31 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Nicolet Bankshares Inc. trimmed its stake in Pfizer Inc. (NYSE:PFEFree Report) by 22.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,528 shares of the biopharmaceutical company’s stock after selling 11,229 shares during the quarter. Nicolet Bankshares Inc.’s holdings in Pfizer were worth $1,311,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Moneta Group Investment Advisors LLC lifted its position in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the last quarter. Norges Bank acquired a new position in Pfizer in the 4th quarter valued at $3,150,472,000. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares during the last quarter. Morgan Stanley grew its position in Pfizer by 10.3% during the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after acquiring an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Pfizer in the 1st quarter valued at about $311,238,000. 68.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, January 31st. Morgan Stanley decreased their price target on Pfizer from $39.00 to $37.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 1st. UBS Group decreased their target price on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. Barclays reduced their price target on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. Finally, Truist Financial reduced their price target on Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Eleven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $36.93.

View Our Latest Research Report on Pfizer

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb acquired 3,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were bought at an average cost of $26.47 per share, with a total value of $79,410.00. Following the completion of the acquisition, the director now owns 9,000 shares in the company, valued at $238,230. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is owned by corporate insiders.

Pfizer Stock Up 0.1 %

Pfizer stock traded up $0.04 during midday trading on Monday, reaching $27.60. The company’s stock had a trading volume of 18,640,023 shares, compared to its average volume of 44,518,758. The stock’s 50-day simple moving average is $28.19 and its 200-day simple moving average is $31.36. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.38 and a quick ratio of 2.05. Pfizer Inc. has a 52-week low of $25.76 and a 52-week high of $44.20. The stock has a market capitalization of $155.84 billion, a P/E ratio of 76.56, a PEG ratio of 1.22 and a beta of 0.62.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.61% and a net margin of 3.62%. The company’s revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.14 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.23 EPS for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Investors of record on Friday, January 26th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.09%. This is a positive change from Pfizer’s previous quarterly dividend of $0.41. The ex-dividend date is Thursday, January 25th. Pfizer’s dividend payout ratio (DPR) is 466.67%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.